Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Natera, Inc. - Common Stock (NQ:NTRA)

207.78 -4.34 (-2.05%)
Streaming Delayed Price Updated: 10:55 AM EST, Feb 23, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Natera, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
News headline image
Natera (NTRA) Q2 Revenue Jumps 32% ↗
Via The Motley Fool
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
Earnings Scheduled For August 7, 2025 ↗
 
Via Benzinga
News headline image
What To Expect From Natera’s (NTRA) Q2 Earnings
Genetic testing company Natera (NASDAQ:NTRA). will be announcing earnings results this Thursday after market hours. Here’s what you need to know. 
Via StockStory
Topics Artificial Intelligence
News headline image
How Do Investors Really Feel About Natera? ↗
 
Via Benzinga
News headline image
$100 Invested In Natera 5 Years Ago Would Be Worth This Much Today ↗
 
Via Benzinga
News headline image
Earnings Scheduled For May 8, 2025 ↗
 
Via Benzinga
News headline image
Preview: Natera's Earnings ↗
 
Via Benzinga
News headline image
Peering Into Natera's Recent Short Interest ↗
 
Via Benzinga
News headline image
Schlumberger, Stellantis And ASML Holding Are Among Top 10 Large Cap Losers Last Week (July 14-July 18): Are The Others In Your Portfolio? ↗
Elevance Health and Waters led the weekly large-cap losers, hit by weak earnings, lowered guidance, and analyst downgrades. 
Via Benzinga
News headline image
$100 Invested In This Stock 5 Years Ago Would Be Worth This Much Today ↗
 
Via Benzinga
News headline image
1 Unprofitable Stock for Long-Term Investors and 2 to Approach with Caution
Running at a loss can be a red flag. Many of these businesses face mounting challenges as competition increases and funding becomes harder to secure. 
Via StockStory
News headline image
1 Growth Stock with Exciting Potential and 2 to Be Wary Of
Growth boosts valuation multiples, but it doesn’t always last forever. Companies that cannot maintain it are often penalized with large declines in market value, a lesson ingrained in investors who... 
Via StockStory
News headline image
Q1 Immuno-Oncology Earnings Review: First Prize Goes to Natera (NASDAQ:NTRA)
Let’s dig into the relative performance of Natera (NASDAQ:NTRA) and its peers as we unravel the now-completed Q1 immuno-oncology earnings season. 
Via StockStory
Topics Artificial Intelligence
News headline image
Here's How Much $100 Invested In Natera 10 Years Ago Would Be Worth Today ↗
 
Via Benzinga
News headline image
1 Volatile Stock to Own for Decades and 2 to Brush Off
Volatility cuts both ways - while it creates opportunities, it also increases risk, making sharp declines just as likely as big gains. This unpredictability can shake out even the most experienced... 
Via StockStory
News headline image
Q1 Rundown: Regeneron (NASDAQ:REGN) Vs Other Immuno-Oncology Stocks
Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let’s have a look at Regeneron (NASDAQ:REGN) and its peers. 
Via StockStory
Topics Artificial Intelligence
News headline image
3 Reasons We Love Natera (NTRA)
Natera has followed the market’s trajectory closely, rising in tandem with the S&P 500 over the past six months. The stock has climbed by 5% to $170 per share while the index has gained 1.1%. 
Via StockStory
Topics Government Stocks
News headline image
Here's How Much You Would Have Made Owning Natera Stock In The Last 10 Years ↗
 
Via Benzinga
News headline image
A Look Back at Immuno-Oncology Stocks’ Q1 Earnings: Exact Sciences (NASDAQ:EXAS) Vs The Rest Of The Pack
As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the immuno-oncology industry, including Exact Sciences (NASDAQ:EXAS) and its peers. 
Via StockStory
Topics Artificial Intelligence
News headline image
NTRA Q1 Earnings Call: Growth in Oncology and Women's Health Drives Guidance Increase
Genetic testing company Natera (NASDAQ:NTRA). reported Q1 CY2025 results beating Wall Street’s revenue expectations, with sales up 36.5% year on year to $501.8 million. The company’s full-year revenue... 
Via StockStory
News headline image
9 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
2 Cash-Heavy Stocks for Long-Term Investors and 1 to Be Wary Of
Companies with more cash than debt can be financially resilient, but that doesn’t mean they’re all strong investments. Some lack leverage because they struggle to grow or generate consistent profits,... 
Via StockStory
News headline image
3 Mid-Cap Stocks Worth Your Attention
Large trillion-dollar companies are tightening their grip on the market, often by acquiring smaller rivals. This trend will likely pick up with new regulatory leadership, but a few mid-sized businesses... 
Via StockStory
News headline image
If You Invested $100 In This Stock 5 Years Ago, You Would Have This Much Today ↗
 
Via Benzinga
News headline image
Here's How Much $100 Invested In Natera 5 Years Ago Would Be Worth Today ↗
 
Via Benzinga
News headline image
8 Analysts Have This To Say About Natera ↗
 
Via Benzinga
News headline image
Natera (NASDAQ:NTRA) Surprises With Strong Q1, Guides for Strong Full-Year Sales
Genetic testing company Natera (NASDAQ:NTRA). announced better-than-expected revenue in Q1 CY2025, with sales up 36.5% year on year to $501.8 million. The company’s full-year revenue guidance of $1.98... 
Via StockStory
News headline image
What To Expect From Natera’s (NTRA) Q1 Earnings
Genetic testing company Natera (NASDAQ:NTRA). will be reporting earnings tomorrow after market hours. Here’s what you need to know. 
Via StockStory
Topics Artificial Intelligence
News headline image
2 Healthcare Stocks on Our Watchlist and 1 to Be Wary Of
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory... 
Via StockStory
Topics Stocks
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.